Clara Rodríguez Fernández, Author at Labiotech.eu - Page 28 of 62

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

CureVac Moderna Therapeutics Biotech Unicorn Battle mRNA

Interview 6 Nov 2017

Battle of the Biotech Unicorns: CureVac vs. Moderna

An interview never seen before. We brought together the founders and CEOs of the two biotech unicorns pioneering mRNA therapy: CureVac in Germany and Moderna Therapeutics in the US. The idea of messenger RNA as a therapy is simple but brilliant: instead of giving a protein to a patient, you give their body the instructions […]

November 6, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

Robertina Sebjanic Aurelia Aurita

News and Trends 4 Nov 2017

Bioart from the Ocean Depths: Underwater Sounds

What can art tell us about the mysteries of underwater life? Robertina Šebjanič explores the fascinating world of jellyfish, shrimps, fish and sea urchins. Robertina Šebjanič is an artist and researcher fascinated by underwater life. Her work explores the relationship between humans and animals, often through an unusual medium: sound. Šebjanič collaborates with other artists, […]

November 4, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

uniQure Nasdaq gene therapy

News and Trends 2 Nov 2017

Close to Launching Gene Therapy, Dutch Biotech Raises Over $91M on the Nasdaq

Update (2/11/2017): uniQure has closed its public offering raising over $91m (€78M) on the Nasdaq, taking advantage of a massive stock jump triggered by the announcement that an improved version of its gene therapy for hemophilia B will enter Phase III trials. Originally published on 24/10/2017 UniQure launched a public offering, perfectly timed with a rise in […]

November 2, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

astrazeneca moderna heart failure mrna

News and Trends 2 Nov 2017

AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure

AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis’ failed heart failure drug Serelaxin. AstraZeneca has signed a deal with US biotech Moderna Therapeutics to co-develop and co-commercialize an mRNA drug encoding for the protein hormone relaxin. The therapy has the same target as Novartis’ Serelaxin (RLX030), a drug that was dropped in March […]

November 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

biogeneration ventures medical biotech fund

News and Trends 1 Nov 2017

Update: Dutch VC Raises €82M for a New European Medical Biotech Fund

Update (1/11/2017): BioGeneration Ventures has surpassed its third round goal of raising €75M by securing €82M. The VC has received extra support from Bristol-Myers Squibb and Johnson & Johnson Innovation. Originally published 27/06/2017 BioGeneration Ventures has secured €66M from Dutch and EU investors that will go towards biotechs developing therapeutics, diagnostics and medical devices. BioGeneration Ventures is a Dutch VC that focuses its investments on […]

November 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Theranexus IPO CNS Narcolepsy Parkinsons Alzheimers

News and Trends 30 Oct 2017

French Biotech Closes €19M IPO to Treat Narcolepsy and Alzheimer’s

Theranexus debuts on Euronext Paris raising €19.6M that will support the development of its pipeline of CNS drugs for narcolepsy, Parkinson’s, Alzheimer’s and neuropathic pain. Theranexus, based in Lyon, starts trading on Euronext Paris today. The company starts off with a market cap of €47.5M after closing a €19.6M IPO. With the money raised, the company […]

October 30, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

Dutch Design Week Biomaterials

News and Trends 28 Oct 2017

Biomaterials Take the Stage at Dutch Design Week

The Dutch Design Week featured several biodesign projects that explore how the future will be shaped by the advance of biotechnology. Let’s have a look at some of them. Celebrated annually in Eindhoven, the Dutch Design Week has become a hotspot where designers share the latest trends and technologies. In the last few years, biodesign […]

October 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

CN Bio Innovations FDA organs on chips

News and Trends 26 Oct 2017

The FDA Recruits British Organs-on-Chips to Speed Up Drug Development

CN Bio Innovations and the FDA have entered a research collaboration to better predict drug safety in drug development by using human organs-on-chips. CN Bio Innovations, a spin-out from the University of Oxford, will be working with scientists from the FDA’s Centre for Drug Evaluation and Research with the aim of integrating organ-on-a-chip technology in the […]

October 26, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

gsk strimvelis uk nice

News and Trends 25 Oct 2017

The UK Recommends the use of GSK’s €594,000 Gene Therapy

Amidst uncertainty about the commercial future of expensive gene therapies, the UK’s NICE has declared GSK’s Strimvelis offers “value for money.” Approved by the EMA last year, Strimvelis is one of the most expensive drugs on the market. Although GSK is offering a money-back guarantee and payment through instalments, the price of the gene therapy, […]

October 25, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

dbv technologies peanut allergy

News and Trends 23 Oct 2017

Peanut Allergy Trial Fails but French Biotech Keeps Pushing for Approval

DBV Technologies plans to go ahead with its peanut allergy treatment despite its failure to meet a primary endpoint in Phase III. Last Friday, DBV Technologies released the results of a Phase III trial that was key to the approval of a treatment to reduce peanut allergy in children. After 12 months, 35% of children […]

October 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Ergomed PeproStat Surgery

News and Trends 23 Oct 2017

A Peptide Reduces Bleeding in Surgery in Phase II Trials

Ergomed has announced positive results in Phase II with PeproStat, a peptide solution to stop bleeding during surgery faster. In a Phase II study that recruited 169 patients across 16 European hospitals, London-based Ergomed has demonstrated that itspipeline’s lead candidate, PeproStat, can reduce the time to achieve hemostasis, that is, for the bleeding to stop, […]

October 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Mariola Sohngen Mologen CEO

Interview 23 Oct 2017

The German CEO Pushing for an Immunotherapy to Treat Cancer and HIV

Mariola Söhngen, CEO of Mologen, discusses biotech entrepreneurship in Germany and her company’s unique immunotherapy against both cancer and HIV. Mariola Söhngen has an outstanding track record as an entrepreneur and leader in biotech and pharma. In 1998, after 10 years working with big pharma, she founded her first company, Bootcamp, to help young professionals […]

October 23, 2017 - 8 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT